GlassScriptPhysician profile
Daniel Sam Sandoval Acierto
NPI 1528670866
$10,673.98
in general payments reported to CMS, 2019-2025
45 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,401 · 2022: $2,888 · 2023: $1,875 · 2024: $2,169 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,384.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.49 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,175.12 | 2021-2024 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $542.85 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.06 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $495.51 | 2021-2024 | Livdelzi, Epclusa |
| Abbott Laboratories | $428.17 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $324.34 | 2024-2025 | |
| United Therapeutics Corporation | $320.53 | 2021-2024 | Tyvaso |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $299.43 | 2025 | Caplyta |
| Grifols USA, LLC | $279.50 | 2022-2023 | Prolastin-C Liquid |
| Novo Nordisk INC | $250.56 | 2021-2025 | Rybelsus, Ozempic |
| Incyte Corporation | $250.41 | 2021-2022 | |
| Intuitive Surgical, INC. | $246.01 | 2022-2023 | Da Vinci Surgical System |
| Lucid Diagnostics INC. | $243.93 | 2022 | |
| Astellas Pharma US INC | $235.19 | 2023-2024 | Veozah, Myrbetriq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sam Acierto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.